The volume of evidence substantiating the role of ACE2 in RAS dysregulation and the pathogenesis of COVID-19 [74,75,76] propelled several human clinical trials using rhACE2 [66,67,68,69] and synthetic Ang(1–7) as therapeutic agents. This evidence concerns the gene ACE2 and COVID-19.